이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sihuan Pharmaceutical Holdings Group 관리

관리 기준 확인 4/4

Sihuan Pharmaceutical Holdings Group's CEO는 Weicheng Guo, Oct2014 에 임명되었습니다 의 임기는 9.67 년입니다. 총 연간 보상은 CN¥ 3.00M, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 HK$ 6.47M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 6.47M. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 8.3 년입니다.

주요 정보

Weicheng Guo

최고 경영자

CN¥3.0m

총 보상

CEO 급여 비율	100.0%
CEO 임기	10yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	8.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Weicheng Guo 의 보수는 Sihuan Pharmaceutical Holdings Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥38m
Mar 31 2024	n/a	n/a	-CN¥46m
Dec 31 2023	CN¥3m	CN¥3m	-CN¥54m
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥3m	CN¥3m	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥144m
Mar 31 2022	n/a	n/a	CN¥141m
Dec 31 2021	CN¥6m	CN¥6m	CN¥427m
Sep 30 2021	n/a	n/a	CN¥681m
Jun 30 2021	n/a	n/a	CN¥945m
Mar 31 2021	n/a	n/a	CN¥727m
Dec 31 2020	CN¥6m	CN¥6m	CN¥508m
Sep 30 2020	n/a	n/a	-CN¥14m
Jun 30 2020	n/a	n/a	-CN¥537m
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥6m	CN¥6m	-CN¥3b
Sep 30 2019	n/a	n/a	-CN¥2b
Jun 30 2019	n/a	n/a	-CN¥1b
Mar 31 2019	n/a	n/a	CN¥238m
Dec 31 2018	CN¥6m	CN¥6m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥6m	CN¥6m	CN¥1b

보상 대 시장: Weicheng 의 총 보상 ($USD 413.40K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 450.61K ).

보상과 수익: Weicheng 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Weicheng Guo (60 yo)

10yrs

테뉴어

CN¥3,000,000

보상

Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...

리더십 팀

이름	위치	테뉴어	보상	소유권
Fengsheng Che	Co-Founder & Executive Chairman	18.4yrs	CN¥7.00m	5.34% HK$ 353.2m
Weicheng Guo	Deputy Chairman & CEO	10yrs	CN¥3.00m	0.12% HK$ 8.1m
Guili Miao	Deputy CEO	2yrs	CN¥5.05m	데이터 없음
Jionglong Zhang	Executive Director	3.9yrs	CN¥646.00k	2.14% HK$ 141.3m
Yanling Chen	Joint Company Secretary & Executive Director	2yrs	CN¥1.77m	데이터 없음
Kin Wai Li	Joint Company Secretary	2yrs	데이터 없음	데이터 없음
Xianhui Meng	Deputy General Manager	no data	CN¥4.26m	데이터 없음

2.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: 460 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fengsheng Che	Co-Founder & Executive Chairman	18.4yrs	CN¥7.00m	5.34% HK$ 353.2m
Weicheng Guo	Deputy Chairman & CEO	18.4yrs	CN¥3.00m	0.12% HK$ 8.1m
Guili Miao	Deputy CEO	2yrs	CN¥5.05m	데이터 없음
Jionglong Zhang	Executive Director	6.5yrs	CN¥646.00k	2.14% HK$ 141.3m
Yanling Chen	Joint Company Secretary & Executive Director	6.5yrs	CN¥1.77m	데이터 없음
Wah Kwong Tsang	Independent Non-Executive Director	11.1yrs	CN¥371.00k	데이터 없음
Xun Zhu	Independent Non-Executive Director	10.7yrs	CN¥371.00k	데이터 없음
Guan Wang	Independent Non-Executive Director	1.5yrs	CN¥202.00k	데이터 없음

8.6yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 460 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

Sihuan Pharmaceutical Holdings Group 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Deputy General Manager recently bought HK$19m worth of stock

Recent updates

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock

Earnings released

New 90-day high - HK$1.03